SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: Ken S. who wrote (1817)5/24/2004 8:54:34 PM
From: tom pope  Read Replies (2) | Respond to of 1870
 
Am I being more than ordinarily dumb tonite, or does this seem counter-intuitive? Unless the disease was actually reversing in the chemo group.

FDA reviewers found that "control" patients who'd received only chemotherapy had been checked for cancer progression at consistently earlier dates than patients who'd gotten Genta's drug. This imbalance could've made cancer progression look worse in the control group, said the FDA


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News